Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

ST Robinson Humphrey Boosts Lilly Rating


The U.S. Food and Drug Administration approved Eli Lilly's (LLY) Strattera drug for attention-deficit/hyperactivity disorder. ST Robinson Humphrey upgraded its rating on Lilly shares to buy.

Analyst Robert Hazlett says the company's Forteo (injectable parathyroid hormone) drug was also approved earlier than expected. He notes Strattera's market is at $2.8 billion and growing. Hazlett says drugs that treat the disorder work pretty well, but are a version of "speed", which is addicting. He says Strattera is non-addicting and could also be widely used by adults. The analyst notes his upgrade is based on the earlier-than-expected approvals signaling a big improvement with Lilly's manufacturing problems at the FDA and the potential for multiple additional approvals in 2003.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus